ADL-5747

CAS No. 850176-30-6

ADL-5747( —— )

Catalog No. M34490 CAS No. 850176-30-6

ADL-5747 (ADL-5747 (free base)) (free base) is a delta opioid receptor agonist used in the treatment of neurological disorders, skin and musculoskeletal disorders, and may be used in the study of postherpetic neuralgia, knee osteoarthritis and pain.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
5MG 342 In Stock
10MG 504 In Stock
25MG 816 In Stock
50MG 1097 In Stock
100MG 1479 In Stock
200MG Get Quote In Stock
500MG 2967 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    ADL-5747
  • Note
    Research use only, not for human use.
  • Brief Description
    ADL-5747 (ADL-5747 (free base)) (free base) is a delta opioid receptor agonist used in the treatment of neurological disorders, skin and musculoskeletal disorders, and may be used in the study of postherpetic neuralgia, knee osteoarthritis and pain.
  • Description
    ADL-5747 (ADL-5747 (free base)) (free base) is a delta opioid receptor agonist used in the treatment of neurological disorders, skin and musculoskeletal disorders, and may be used in the study of postherpetic neuralgia, knee osteoarthritis and pain.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Endocrinology/Hormones
  • Target
    Opioid Receptor
  • Recptor
    Opioid Receptor
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    850176-30-6
  • Formula Weight
    392.49
  • Molecular Formula
    C24H28N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    OC1=C(C2=CC3(OC=4C2=CC=CC4)CCNCC3)C=CC(C(N(CC)CC)=O)=C1
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

molnova catalog
related products
  • AT-121

    AT-121 is a dual μ-opioid and neuropeptide receptor partial agonist (Kis 16.49 and 3.67 nM, respectively).

  • Eluxadoline

    A potent, selective, orally bioavailable μ-opioid receptor agonist and a δ-opioid receptor antagonist for the treatment of diarrhoea-predominant irritable bowel syndrome (IBS-D).

  • BPR1M97

    BPR1M97 is a mu opioid receptor (MOP) and neuropeptide-orphin FQ (NOP) receptor agonist with blood-brain barrier permeability and potency.